Table 1.
Baseline Characteristics of Patients in the Entire Cohort
| All Patients ( n = 607) | ETV ( n = 248) | TDF ( n = 359) | P | ||
|---|---|---|---|---|---|
| Age, years | 44.45 ± 13.44 | 45.54 ± 13.69 | 43.69 ± 13.22 | .097 | |
| Gender, male (%) | 397 (65.4%) | 178 (71.8%) | 219 (61.0%) | .006 | |
| HBeAg positivity,* n (%) | 148 (24.4%) | 52 (21.1%) | 96 (26.7%) | .109 | |
| HBV DNA (log IU/mL) | 5.98 ± 1.63 | 5.93 ± 1.68 | 6.01 ± 1.57 | .553 | |
| Creatinine (mg/dL) | 0.81 ± 0.19 | 0.85 ± 0.25 | 0.79 ± 0.13 | <.001 | |
| AST (IU/L) | 72.59 ± 112.07 | 75.90 ± 131.90 | 70.25 ± 95.72 | .545 | |
| ALT (IU/L) | 108.61 ± 153.83 | 110.00 ± 165.88 | 107.63 ± 145.01 | .853 | |
| ALP (IU/L) | 86.39 ± 42.42 | 87.77 ± 31.73 | 83.26 ± 30.42 | .095 | |
| GGT (IU/L) | 53.22 ± 64.98 | 58.56 ± 71.05 | 49.48 ± 60.22 | .111 | |
| Albumin (g/dL) | 4.04 ± 0.53 | 3.99 ± 0.57 | 4.07 ± 0.49 | .070 | |
| Bilirubin (mg/dL) | 1.13 ± 2.20 | 1.03 ± 1.33 | 1.20 ± 2.63 | .386 | |
| Protrombin time (s) | 14.26 ± 2.43 | 14.43 ± 2.70 | 14.16 ± 2.26 | .271 | |
| INR | 1.10 ± 0.19 | 1.12 ± 0.19 | 1.09 ± 0.19 | .068 | |
| AFP (ng/mL) | 6.63 ± 13.83 | 7.95 ± 18.08 | 5.69 ± 9.72 | .075 | |
| Platelet (×1000/mm3) | 192.09 ± 67.47 | 180.00 ± 66.86 | 200.49 ± 66.71 | <.001 | |
| Diabetes mellitus, n (%) | 91 (15.0%) | 51 (20.6%) | 40 (11.1%) | .001 | |
| Severity of liver disease, n (%) | |||||
| Noncirrhosis | 442 (72.8%) | 159 (64.1%) | 283 (78.8%) | <.001 | |
| Cirrhosis | 165 (27.2%) | 89 (35.9%) | 76 (21.2%) | ||
| Compensated cirrhosis | 128 (21.1%) | 63 (25.4%) | 65 (18.1%) | ||
| Decompensated cirrhosis | 37 (6.1%) | 26 (10.5%) | 11 (3.1%) | ||
| Follow-up, months | 51.71 ± 33.58 | 58.58 ± 37.90 | 46.96 ± 29.37 | <.001 | |
ETV, entecavir; TDF, tenofovir disoproxil fumarate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; INR, international normalized ratio; AFP, alpha-fetoprotein.
*Not available in 1 patient in the ETV cohort.